Fundamentals of Clinical Pharmacology of ADCs
Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since the first ADC, Gemtuzumab-ozogamicin (brand name: Mylotarg), was approved for the treatment of CD33-positive acute myeloid … Read more